Sign Up
Stories
ABBio Innovates Antibody Development
Share
AB Science's Medical Breakthrough Webcas...
ABIONYX Pharma Files 2023 Document
ACTICOR BIOTECH Delays Key Documents
ACTICOR BIOTECH: Financial Report Postpo...
AEON Biopharma Advances Migraine Treatme...
ANJESO Drug Insight and Market Forecast
Overview
API
ABBio, a Dundee-based company established in 2020, focuses on developing distinctive antibodies for diverse diseases, notably a specialized line of p53 antibodies. With a small workforce of 3 employees, ABBio is a privately owned firm led by CEO James Clark Ph.D., with funding support from investors like Innova Partnerships.
Ask a question
How do ABBio's unique antibodies differ from conventional treatments?
How might ABBio's success influence the landscape of antibody therapy research?
What impact could ABBio's innovations have on the pharmaceutical industry?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage
pitch